<DOC>
	<DOCNO>NCT02254668</DOCNO>
	<brief_summary>Randomized prospective multi-center imaging study investigate impact different immunosuppressive protocol ( Everolimus ( Certican® ) Mycophenolate mofetil ( CellCept® ) ) cardiac allograft vasculopathy ( CAV ) heart transplant patient . Maximal intima-thickness visualized optical coherence tomography ( OCT ) ass progression CAV .</brief_summary>
	<brief_title>Intracoronary Analysis Cardiac Allograft Vasculopathy Means Optical Coherence Tomography</brief_title>
	<detailed_description>In summary , aim study examine effect immunosuppressive agent Everolimus ( Certican ) development cardiac allograft vasculopathy ( CAV ) . Therefore study divide three section : Substudy 1 : Evaluation morphological difference CAD CAV . Substudy 2 : Analysis cardiovascular risk factor ( e.g . hypertension ) specific immunosuppressive protocol patient CAV . Substudy 3 : Prospective , randomized analysis influence different immunosuppressive protocol patient CAV . Primary endpoint study adaption intimal thickness 10 year , analyse mean optical coherence tomography . In addition explanation important in- exclusion criterion list : Inclusion Criteria : - Patients heart transplantation - Patients coronary artery disease ( CAD ) - Age 18-80 year Exclusion Criteria : - Contraindication Everolimus/Sirolimus adjuvants - Renal insufficiency ( Creatinine &gt; 265 µmol/l ) - Cardiogenic shock patient Killip*-Class III IV ( *name ) - Pregnant breast feeding female - insufficient contraception ( substudy 3 )</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patients heart transplantation Patient coronary artery disease Age 18 80 year Renal insufficiency ( &gt; 265 µmol/l ) Incapability give inform consent Cardiogenic shock patient KILLIP III IV pregnant breast feeding female insufficient contraception ( substudy 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>intima</keyword>
	<keyword>thickness</keyword>
	<keyword>transplantation</keyword>
	<keyword>cardiology</keyword>
	<keyword>immunosuppression</keyword>
</DOC>